Reoccurrence after 2 stem cell transplant failures with metastasis to pancreas, liver, skull, lungs and abdominal lining5/95 44 yr. old female diagnosed w/reoccurrence of Breast Cancer 4 ½ months after 2 stem cell back to back bone marrow transplants from cancer clinic in Los Angeles.Metastasis to skull, abdominal lining, lungs, pancreas, & liver 6/95 initiated an aggressive oral nutraceutical program.8/95 CAT & bone scans indicate absence of all tumors 617 inflammatory breast cancer case subjects in a nested case–control study from the Breast Cancer Surveillance Consortium database (1994–2009), reported Catherine Schairer, PhD, of the National Cancer Institute, and colleagues. “We also included 1,151 noninflammatory, locally advanced, invasive breast cancers with chest wall/breast skin involvement, 7,600 non inflammatory invasive case subjects without chest wall/breast skin involvement, and 93,654 control subjects matched to case subjects on age and year at diagnosis, and mammography registry.
The prognosis, or likely outcome, for a patient diagnosed with cancer is often viewed as the chance that the cancer will be treated successfully and that the patient will recover completely. Many factors can influence a cancer patient’s prognosis, including the type and location of the cancer, the stage of the disease, the patient’s age and overall general health, and the extent to which the patient’s disease responds to treatment.
Because inflammatory breast cancer usually develops quickly and spreads aggressively to other parts of the body, women diagnosed with this disease, in general, do not survive as long as women diagnosed with other types of breast cancer. It is important to keep in mind, however, that survival statistics are based on large numbers of patients and that an individual woman’s prognosis could be better or worse, depending on her tumor characteristics and medical history. Women who have inflammatory breast cancer are encouraged to talk with their doctor about their prognosis, given their particular situation.
Ongoing research, especially at the molecular level, will increase our understanding of how inflammatory breast cancer begins and progresses. This knowledge should enable the development of new treatments and more accurate prognoses for women diagnosed with this disease. It is important, therefore, that women who are diagnosed with inflammatory breast cancer talk with their doctor about the option of participating in a clinical trial.